» Articles » PMID: 39217250

Reversible Control of Kinase Signaling Through Chemical-induced Dephosphorylation

Overview
Journal Commun Biol
Specialty Biology
Date 2024 Aug 31
PMID 39217250
Authors
Affiliations
Soon will be listed here.
Abstract

The coordination between kinases and phosphatases is crucial for regulating the phosphorylation levels of essential signaling molecules. Methods enabling precise control of kinase activities are valuable for understanding the kinase functions and for developing targeted therapies. Here, we use the abscisic acid (ABA)-induced proximity system to reversibly control kinase signaling by recruiting phosphatases. Using this method, we found that the oncogenic tyrosine kinase BCR::ABL1 can be inhibited by recruiting various cytoplasmic phosphatases. We also discovered that the oncogenic serine/threonine kinase BRAF(V600E), which has been reported to bypass phosphorylation regulation, can be positively regulated by protein phosphatase 1 (PP1) and negatively regulated by PP5. Additionally, we observed that the dual-specificity kinase MEK1 can be inhibited by recruiting PP5. This suggests that bifunctional molecules capable of recruiting PP5 to MEK or RAF kinases could be promising anticancer drug candidates. Thus, the ABA-induced dephosphorylation method enables rapid screening of phosphatases to precisely control kinase signaling.

References
1.
Swingle M, Honkanen R, Ciszak E . Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5. J Biol Chem. 2004; 279(32):33992-9. DOI: 10.1074/jbc.M402855200. View

2.
Haling J, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W . Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell. 2014; 26(3):402-413. DOI: 10.1016/j.ccr.2014.07.007. View

3.
Chen P, Hu Z, An E, Okeke I, Zheng S, Luo X . Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs). ACS Chem Biol. 2021; 16(12):2808-2815. PMC: 10437008. DOI: 10.1021/acschembio.1c00693. View

4.
Tsai C, Nussinov R . The molecular basis of targeting protein kinases in cancer therapeutics. Semin Cancer Biol. 2013; 23(4):235-42. DOI: 10.1016/j.semcancer.2013.04.001. View

5.
Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K . Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012; 11(11):873-86. DOI: 10.1038/nrd3847. View